Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2016—Qiagen has entered into a licensing and co-development agreement with Munich-based Therawis Diagnostics to develop and commercialize predictive assays in oncology. An initial project will be to develop and market PITX2 as a marker to predict the effectiveness of anthracycline treatment in triple-negative and other high-risk breast cancer patients.
August 2016—The Tissue-Tek Cryo3 Flex Cryostat, from Sakura Finetek USA, produces sections from 1 to 99 µm using a temperature-controlled blade holder and a 3-D precision chuck to accurately align the block face to the blade, reducing user’s trimming time and preserving specimens.
July 2016—SciGene introduced its MicroFISH Assay System, a clinically validated method combining microvolume, multiwell slides with SciGene slide processing instruments to perform routine cellular fluorescence in situ hybridization in cytogenetic laboratories.
July 2016—Invitrogen SuperScript IV VILO Master Mix from Thermo Fisher Scientific is a cDNA reaction master mix designed for two-step quantitative PCR (RT-qPCR) applications. The master mix format uses variable input, linear output technology and combines optimized buffer conditions with Invitrogen SuperScript IV reverse transcriptase.
Under terms of an agreement with Illumina, ArcherDx will lead the development of a series of diagnostic tests, using ArcherDx’s Anchored Multiplex PCR chemistry, that will run on the Illumina MiSeqDx instrument.
July 2016—Genomics plc, a company that develops algorithms and software solutions to uncover the relationships between genetic variation and human disease, has entered into a research collaboration with DNAnexus, a cloud-based genome informatics and data management platform.
July 2016—Bio-Rad Laboratories released its Liquichek Maternal Serum II Control, a frozen liquid human serum-based material designed to monitor the precision of laboratory test procedures used during maternal serum second trimester screening.
July 2016—Bioo Scientific has launched the Nextflex BRCA1 and BRCA2 Amplicon Panel for FFPE Illumina-compatible sequencing. The panel detects clinically relevant somatic mutations in DNA isolated from formalin-fixed, paraffin-embedded samples to facilitate variant discovery and confirmation.
July 2016—Protagen gained CE marking for its Multilisa BICD2 test. BICD2 is a proprietary biomarker discovered by Protagen using the SeroTag technology platform.
July 2016—Oxford Gene Technology introduced its SureSeq FFPE DNA Repair Mix for repairing a broad range of damage in formalin-fixed, paraffin-embedded–derived DNA.
